Myeloma therapies
| Treatment . | N (%) . |
|---|---|
| Initial cycle | |
| Initial daratumumab-based regimen, n (%) | |
| Dara-VCd | 11 (55) |
| Dara-Vd | 9 (45) |
| Daratumumab formulation, n (%) | |
| IV | 3 (15) |
| Subcutaneous | 17 (85) |
| Median time from the day of admission to daratumumab initiation (range), d | 3 (0-10) |
| Subsequent cycles | |
| Lenalidomide added in subsequent cycles, n (%) | |
| Cycle 2 | 8 (40) |
| Cycle 3 | 4 (20) |
| Cycle 4 | 1 (5) |
| Cycle 5 | 1 (5) |
| Stem cell collection, n (%) | 8 (40) |
| Underwent ASCT, n (%) | 3 (15) |
| Treatment . | N (%) . |
|---|---|
| Initial cycle | |
| Initial daratumumab-based regimen, n (%) | |
| Dara-VCd | 11 (55) |
| Dara-Vd | 9 (45) |
| Daratumumab formulation, n (%) | |
| IV | 3 (15) |
| Subcutaneous | 17 (85) |
| Median time from the day of admission to daratumumab initiation (range), d | 3 (0-10) |
| Subsequent cycles | |
| Lenalidomide added in subsequent cycles, n (%) | |
| Cycle 2 | 8 (40) |
| Cycle 3 | 4 (20) |
| Cycle 4 | 1 (5) |
| Cycle 5 | 1 (5) |
| Stem cell collection, n (%) | 8 (40) |
| Underwent ASCT, n (%) | 3 (15) |
ASCT, autologous stem cell transplant.